文献速递银屑病与炎症性皮肤病

Orismilast治疗中重度银屑病:16周随机双盲安慰剂对照2b期剂量探索试验(IASOS)

Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS).
PubMed 文献 · J Am Acad Dermatol · 2023-11-10

IASOS试验为多中心、随机、双盲、安慰剂对照2b期16周剂量探索研究,纳入202例中重度斑块状银屑病成人患者,按1:1:1:1随机接受Orismilast 20、30、40 mg或安慰剂每日两次。结果显示Orismilast较安慰剂显著改善PASI百分比变化(-52.6%至-63.7% vs -17.3%,均P<.001),PASI75和PASI90应答率更高,安全性符合PDE4抑制预期,存在剂量依赖性耐受性效应。

要点

  • Orismilast 20–40 mg每日两次治疗16周,PASI改善显著优于安慰剂(均P<.001)。
  • PASI75应答率39.5%–49.0%,PASI90应答率22.0%–28.3%(20和40 mg组P<.05)。
  • 安全性符合PDE4抑制预期,可见剂量依赖性耐受性效应。

核心结论

  • Orismilast在中重度斑块状银屑病中较安慰剂显示出更优疗效,安全性特征与PDE4抑制一致。

研究设计与样本

  • 多中心、随机(1:1:1:1至Orismilast 20、30、40 mg或安慰剂,每日两次)、双盲、安慰剂对照、平行组、2b期、16周剂量探索研究(NCT05190419)。
  • 纳入成人中重度斑块状银屑病患者,共202例随机分组,疗效终点采用多重插补分析。

主要发现

  • 第16周PASI百分比变化:Orismilast组-52.6%至-63.7%,安慰剂组-17.3%,所有P<.001。
  • 第16周PASI75:Orismilast组39.5%–49.0%(P<.05),安慰剂组16.5%。
  • 第16周PASI90:Orismilast组22.0%–28.3%(20和40 mg组P<.05),安慰剂组8.3%。
  • 安全性发现符合PDE4抑制预期,观察到剂量依赖性耐受性效应。

关键数值与推荐

  • 主要终点为第16周PASI较基线的百分比变化。
  • PASI75和PASI90为第16周关键疗效应答指标。

临床怎么用

  • Orismilast每日两次口服在中重度斑块状银屑病中显示出较安慰剂显著的疗效,支持进一步临床开发。

局限性

  • 样本量小。
  • 组间疾病严重程度不平衡(Orismilast组重度比例更高)。
  • 研究持续时间有限。
  • 研究人群多样性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Orismilast is a novel oral phosphodiesterase-4 (PDE4) B/D inhibitor being investigated as a potential treatment for moderate-to-severe psoriasis. OBJECTIVE: To evaluate efficacy and safety of orismilast modified-release formulation in moderate-to-severe psoriasis. METHODS: This multicenter, randomized (1:1:1:1 to 20, 30, 40 mg orismilast or placebo, twice daily), double-blinded, placebo-controlled, parallel-group, phase 2b, 16-week, dose-ranging study evaluated orismilast in adults with moderate-to-severe plaque psoriasis (NCT05190419). Efficacy end points were analyzed using multiple imputation. RESULTS: Of 202 randomized patients, baseline characteristics were balanced across arms, except greater severe disease proportions for orismilast vs placebo. Orismilast showed significant improvements in the primary end point, percentage change in Psoriasis Area and Severity Index (PASI), from baseline to week 16 (orismilast -52.6% to -63.7% and placebo, -17.3%; all P <.001). Greater proportions receiving orismilast achieved PASI75 (39.5%-49.0%; P <.05) and PASI90 (22.0%-28.3%; P <.05 for 20 and 40 mg) vs placebo (PASI75, 16.5% and PASI90, 8.3%) at week 16. Safety findings were as expected with PDE4 inhibition; dose-dependent tolerability effects observed. LIMITATIONS: Small sample size, disease severity imbalance between groups, limited duration and diversity in study population. CONCLUSION: Orismilast demonstrated greater efficacy vs placebo and a safety profile in line with PDE4 inhibition.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Warren RB, French LE, Blauvelt A, et al. Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS). J Am Acad Dermatol. 2023. PMID: 37951245. doi:10.1016/j.jaad.2023.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。